John Crisham is a partner in Kirkland's Washington, D.C. office, focusing generally on complex commercial litigation, products liability litigation and appellate litigation. His experience includes all aspects of litigation, including discovery, motions practice and appeal.
Mutual Pharm. Co. v. Bartlett, 133 S. Ct. 2466 (2013): secured U.S. Supreme Court decision holding that the Hatch-Waxman Act preempts state-law tort claims targeting the design/composition of generic drug products.
Henderson v. Palmer, --- F.3d ----, 2013 WL 4838799 (6th Cir. 2013): on behalf of pro bono client, secured reversal of district court's denial of habeas corpus petition, allowing client to assert his claims on the merits in the district court.
Jones v. Abbott Laboratories, M2013-769-SC-R23-CQ (Tenn. 2013): secured Tennessee Supreme Court decision denying certified question appeal from a federal district court on the existence of the learned-intermediary doctrine in Tennessee.
Mylan Pharms., Inc. v. Sebelius, 856 F. Supp. 2d 196 (D.D.C. 2012): successfully defended FDA decision awarding client 180-day exclusivity for sales of generic modafinil (Provigil®).
Cook v. Rockwell Int'l Corp., 618 F.3d 1127 (10th Cir. 2010): secured reversal of $926 million judgment in favor of plaintiff class in nuclear environmental contamination case on a variety of grounds, including erroneous interpretation of the federal Price-Anderson Act establishing claims for nuclear-related liability, erroneous approach to preemption of state law by federal nuclear safety standards, and erroneous interpretation of the Colorado common law of trespass and nuisance.
United States v. Philip Morris USA, Inc., et al., 566 F.3d 1095 (D.C. Cir. 2009): secured reversal and remand of client-specific rulings made by district court in $280 billion RICO/health care recovery action brought by the United States Department of Justice.
Counsel for Ranbaxy Laboratories and Baxter Healthcare Corporation in various product-liability cases in state and federal courts involving questions of federal preemption.
Counsel for Teva Pharmaceuticals and related entities in nationwide products liability litigation involving "unapproved" drugs.
Counsel for Teva Pharmaceuticals and related entities in complex multi-district litigation involving drug pricing and alleged Medicaid/Medicare fraud.
Counsel for Teva Pharmaceuticals and related entities in major product liability litigation.
Counsel for ConocoPhillips Company in case alleging personal injuries on oil rigs and platforms in the North Sea.
U.S. Supreme Court
U.S. Court of Appeals for the Third Circuit
U.S. Court of Appeals for the Fourth Circuit
U.S. Court of Appeals for the Sixth Circuit
U.S. Court of Appeals for the Seventh Circuit
U.S. Court of Appeals for the Tenth Circuit
U.S. Court of Appeals for the D.C. Circuit
U.S. Court of Appeals for the Federal Circuit
U.S. District Court for the District of Columbia